Search Results - "Seidl, Dániel"

Identification of incompletely penetrant variants and interallelic interactions in autosomal recessive disorders by a population‐genetic approach by Mikó, Ágnes, Kaposi, Ambrus, Schnabel, Karolina, Seidl, Dániel, Tory, Kálmán

“…We aimed to identify incompletely penetrant (IP) variants and interallelic interactions in autosomal recessive disorders by a population‐genetic approach…”
Get full text

Interaction of tumor cells with the microenvironment by Ungefroren, Hendrik, Sebens, Susanne, Seidl, Daniel, Lehnert, Hendrik, Hass, Ralf

“…Recent advances in tumor biology have revealed that a detailed analysis of the complex interactions of tumor cells with their adjacent microenvironment (tumor…”
Get full text

Characterization of spontaneous and TGF-β-induced cell motility of primary human normal and neoplastic mammary cells in vitro using novel real-time technology by Mandel, Katharina, Seidl, Daniel, Rades, Dirk, Lehnert, Hendrik, Gieseler, Frank, Hass, Ralf, Ungefroren, Hendrik

“…The clinical complications derived from metastatic disease are responsible for the majority of all breast cancer related deaths. Since cell migration and…”
Get full text

Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort by Zschäbitz, Stefanie, Biernath, Nadine, Hilser, Thomas, Höllein, Alexander, Zengerling, Friedemann, Cascucelli, Jozefina, Paffenholz, Pia, Seidl, Daniel, Lutz, Christoph, Schlack, Katrin, Kingreen, Dorothea, Klümper, Niklas, Ivanyi, Philipp, von Amsberg, Gunhild, Heers, Hendrik, Roghmann, Florian, Tauber, Robert L., Cathomas, Richard, Hofer, Luisa, Niegisch, Günter, Klee, Melanie, Ehrenberg, Roland, Hassler, Andreas, Hadaschik, Boris A., Grünwald, Viktor, Darr, Christopher

“…Administration of enfortumab vedotin in real-world patients was feasible with an acceptable toxicity profile. Antitumor activity in our cohort was comparable…”
Get full text

Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head-and-neck cancer? by Rades, Dirk, Seidl, Daniel, Janssen, Stefan, Bajrovic, Amira, Hakim, Samer G, Wollenberg, Barbara, Schild, Steven E

“…Highlights • Cisplatin alone appeared associated with fewer adverse events than cisplatin plus 5-FU. • Cisplatin alone appeared to result in better overall…”
Get full text

MO044: Cellular mechanism of the exceptional dominant transmission in NPHS2-associated glomerulopathy by Seidl, Dániel, Antal-Kónya, Violetta, Schay, Gusztáv, Bertholet-Thomas, Aurélia, Török, György, Mollet, Geraldine, Kellermayer, Miklós, Antignac, Corinne, Tory, Kálmán

“…Abstract BACKGROUND AND AIMS Mutations of NPHS2 cause autosomal recessive steroid-resistant nephrotic syndrome (SRNS). The encoded podocin, a key component of…”
Get full text

Correction: Characterization of Spontaneous and TGF-β-Induced Cell Motility of Primary Human Normal and Neoplastic Mammary Cells In Vitro Using Novel Real-Time Technology by Mandel, Katharina, Seidl, Daniel, Rades, Dirk, Lehnert, Hendrik, Gieseler, Frank, Hass, Ralf, Ungefroren, Hendrik

“…The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. (2013) Correction:…”
Get full text

Comparing two lower-dose cisplatin programs for radio-chemotherapy of locally advanced head-and-neck cancers by Rades, Dirk, Seidl, Daniel, Janssen, Stefan, Strojan, Primoz, Karner, Katarina, Bajrovic, Amira, Hakim, Samer G., Wollenberg, Barbara, Schild, Steven E.

“…Radio-chemotherapy is a common treatment for locally advanced squamous cell head-and-neck cancers (LA-SCCHN). Cisplatin (100 mg/m 2 ) every 3 weeks is very…”
Get full text

Linearization errors in discrete goal-oriented error estimation by Granzow, Brian N., Seidl, D. Thomas, Bond, Stephen D.

“…This paper is concerned with goal-oriented a posteriori error estimation for nonlinear functionals in the context of nonlinear variational problems solved with…”
Get full text

Bayesian optimal experimental design for constitutive model calibration by Ricciardi, Denielle E., Seidl, Daniel Thomas, Lester, Brian T., Jones, Amanda Rose, Jones, Elizabeth M.C.

“…Computational simulation is increasingly relied upon for high/consequence engineering decisions, which necessitates a high confidence in the calibration of and…”
Get full text

Treatment options and outcome of patients with metastatic renal cell carcinoma with brain or bone metastases: Real world evidence from a German retrospective multi-center analysis by Paffenholz, Pia, Ivanyi, Philipp, Casuscelli, Jozefina, Stelmach, Ramona, Guer, Melis, Schlack, Katrin, Darr, Christopher, Rinderknecht, Emily, Hilser, Thomas, Flegar, Luka, Klee, Melanie, Seidl, Daniel, Handke, Analena, Nestler, Tim, Mattigk, Angelika, Augustin, Marinela, Hijazi, Sameh, Rehlinghaus, Marc, Heidenreich, Axel, Gruenwald, Viktor

“…387 Background: Brain (BM) and bone metastases (BOM) in renal cell carcinoma (RCC) are associated with poor outcome. We evaluated real-world treatment…”
Get full text

Safety and efficacy of enfortumab vedotin in patients with metastatic/locally advanced urothelial cancer: Real-world evidence from a European database by Zschaebitz, Stefanie, Klümper, Niklas, Büttner, Thomas, Holzwarth, Nina, Biernath, Nadine, Höllein, Alexander, Niegisch, Guenter, Seidl, Daniel, Aydogdu, Can, Handke, Analena, Paffenholz, Pia, Schlack, Katrin, Cathomas, Richard, Erne, Eva, Banek, Severine, Tauber, Robert, Casuscelli, Jozefina, Seitz, Anna Katharina, Grünwald, Viktor, Darr, Christopher

“…553 Background: Enfortumab vedotin (EV) is an antibody drug conjugate targeting Nectin-4. It was approved by EMA/FDA in patients (pts) with metastatic/ locally…”
Get full text

Real world evidence from a retrospective multi-center analysis on first-line therapy for metastatic renal cell carcinoma with non-clear cell and/or sarcomatoid histologies by Paffenholz, Pia, Zschaebitz, Stefanie, Casuscelli, Jozefina, Rinderknecht, Emily, Mattigk, Angelika, Gür, Melis, Ivanyi, Philipp, Hilser, Thomas, Darr, Christopher, Mandal, Subhajit, Schlack, Katrin, Seidl, Daniel, Handke, Analena, Klee, Melanie, Nestler, Tim, Rehlinghaus, Marc, Hijazi, Sameh, Heidenreich, Axel, Grünwald, Viktor, Schostak, Martin

“…392 Background: Papillary (pRCC), chromophob (chRCC) and predominantly sarcomatoid renal cell carcinoma (sRCC) as well as RCC with sarcomatoid features are…”
Get full text

Non-Whole-Gland High-Intensity Focused Ultrasound vs Whole-Gland High-Intensity Focused Ultrasound for Management of Localized Prostate Cancer: 1-Year Oncological and Functional Outcomes by Lei, Ye, Zanker, Patrick, Yildiz, Serdar, Hancke, Kristofina, Seidl, Daniel, Koch, Orlando, Schwentner, Christian, Mundhenk, Jens

“…The aim of the study was to compare the oncological and functional outcomes in localized prostate cancer patients who received non-whole-gland high-intensity…”
Get more information

DIC Challenge 2.0: Developing Images and Guidelines for Evaluating Accuracy and Resolution of 2D Analyses: Focus on the Metrological Efficiency Indicator by Reu, P. L., Blaysat, B., Andó, E., Bhattacharya, K., Couture, C., Couty, V., Deb, D., Fayad, S. S., Iadicola, M. A., Jaminion, S., Klein, M., Landauer, A. K., Lava, P., Liu, M., Luan, L. K., Olufsen, S. N., Réthoré, J, Roubin, E., Seidl, D. T., Siebert, T., Stamati, O., Toussaint, E., Turner, D., Vemulapati, C. S. R., Weikert, T., Witz, J. F., Witzel, O., Yang, J.

“…Background The DIC Challenge 2.0 follows on from the work accomplished in the first Digital Image Correlation (DIC) Challenge Reu et al. (Experimental…”
Get full text

Prognostic Factors After Definitive Radio(Chemo)Therapy of Locally Advanced Head and Neck Cancer by Seidl, Daniel, Janssen, Stefan, Strojan, Primoz, Bajrovic, Amira, Schild, Steven E, Rades, Dirk

“…To identify predictors of locoregional control (LRC) and overall survival (OS) after definitive radio(chemo)therapy for squamous cell carcinoma of the head and…”
Get full text

Comparison of weekly administration of cisplatin versus three courses of cisplatin 100 mg/m(2) for definitive radiochemotherapy of locally advanced head-and-neck cancers by Rades, Dirk, Seidl, Daniel, Janssen, Stefan, Bajrovic, Amira, Karner, Katarina, Strojan, Primoz, Schild, Steven E

“…To compare definitive radiochemotherapy with weekly administration of 30-40 mg/m(2) of cisplatin to 100 mg/m(2) of cisplatin on days 1, 22 and 43 for outcomes…”
Get full text

Radiochemotherapy with Paclitaxel for Recurrent Previously Irradiated Squamous Cell Carcinoma of the Head and Neck by Rades, Dirk, Seidl, Daniel, Wollenberg, Barbara, Schild, Steven E, Hakim, Samer G

“…Locoregional recurrences of squamous cell carcinoma of the head and neck (SCCHN) are difficult to treat. If radiotherapy was included in the primary treatment,…”
Get full text

Prognostic Factors in Patients Irradiated for Recurrent Head-and-Neck Cancer by Seidl, Daniel, Schild, Steven E, Wollenberg, Barbara, Hakim, Samer G, Rades, Dirk

“…Many patients with recurrent head-and-neck cancer have poor outcomes. Predictive factors allowing judgment of the patient's prognosis are important for…”
Get full text

Comparison of weekly administration of cisplatin versus three courses of cisplatin 100 mg/m2 for definitive radiochemotherapy of locally advanced head-and-neck cancers by Rades, Dirk, Seidl, Daniel, Janssen, Stefan, Bajrovic, Amira, Karner, Katarina, Strojan, Primoz, Schild, Steven E

“…Background To compare definitive radiochemotherapy with weekly administration of 30-40 mg/m.sup.2 of cisplatin to 100 mg/m.sup.2 of cisplatin on days 1, 22 and…”
Get full text